Posted by Amber O'Connor on Mar 19th, 2024
UiPath (NYSE:PATH – Free Report) had its price objective raised by Bank of America from $26.00 to $30.00 in a research report report published on Thursday, Benzinga reports. The brokerage currently has a buy rating on the healthcare...
More of this article »